BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) – Analysts at Jefferies Financial Group issued their FY2022 earnings per share (EPS) estimates for BeiGene in a research note issued on Wednesday, November 16th. Jefferies Financial Group analyst C. Lui forecasts that the company will post earnings of ($17.17) per share for the year. The consensus estimate for BeiGene’s current full-year earnings is ($17.69) per share. Jefferies Financial Group also issued estimates for BeiGene’s FY2023 earnings at ($13.44) EPS and FY2025 earnings at ($4.42) EPS.
BGNE has been the topic of a number of other reports. Morgan Stanley boosted their target price on BeiGene from $290.00 to $295.00 and gave the stock an “overweight” rating in a report on Thursday, October 13th. Cowen raised their price objective on BeiGene from $200.00 to $213.00 in a research report on Thursday, November 10th. StockNews.com raised BeiGene from a “sell” rating to a “hold” rating in a research note on Saturday. Guggenheim raised their target price on BeiGene to $210.00 in a report on Tuesday, November 15th. Finally, Cowen boosted their target price on BeiGene from $200.00 to $213.00 in a research note on Thursday, November 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $239.50.
BeiGene Stock Performance
Institutional Investors Weigh In On BeiGene
A number of institutional investors have recently bought and sold shares of the stock. Capital International Investors boosted its stake in shares of BeiGene by 11.2% in the first quarter. Capital International Investors now owns 7,055,295 shares of the company’s stock valued at $1,337,378,000 after purchasing an additional 711,396 shares during the period. Primecap Management Co. CA lifted its stake in BeiGene by 17.5% during the third quarter. Primecap Management Co. CA now owns 4,734,979 shares of the company’s stock valued at $638,370,000 after buying an additional 703,530 shares in the last quarter. Pictet Asset Management SA lifted its stake in BeiGene by 301.5% during the second quarter. Pictet Asset Management SA now owns 308,919 shares of the company’s stock valued at $49,999,000 after buying an additional 231,976 shares in the last quarter. Bank of America Corp DE lifted its position in shares of BeiGene by 77.1% in the first quarter. Bank of America Corp DE now owns 414,466 shares of the company’s stock worth $78,169,000 after purchasing an additional 180,470 shares in the last quarter. Finally, Bridgewater Associates LP raised its position in BeiGene by 67.3% during the first quarter. Bridgewater Associates LP now owns 383,818 shares of the company’s stock valued at $72,388,000 after acquiring an additional 154,335 shares in the last quarter. 51.77% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other BeiGene news, CEO John Oyler sold 30,520 shares of the company’s stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $153.50, for a total value of $4,684,820.00. Following the sale, the chief executive officer now directly owns 2,070,913 shares of the company’s stock, valued at $317,885,145.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other BeiGene news, insider Xiaodong Wang sold 1,987 shares of the firm’s stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $210.14, for a total transaction of $417,548.18. Following the transaction, the insider now directly owns 5,629,556 shares of the company’s stock, valued at approximately $1,182,994,897.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John Oyler sold 30,520 shares of the firm’s stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $153.50, for a total transaction of $4,684,820.00. Following the completion of the sale, the chief executive officer now owns 2,070,913 shares of the company’s stock, valued at approximately $317,885,145.50. The disclosure for this sale can be found here. Insiders sold 57,507 shares of company stock valued at $10,273,368 over the last 90 days. Corporate insiders own 7.50% of the company’s stock.
BeiGene Company Profile
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).
- Get a free copy of the StockNews.com research report on BeiGene (BGNE)
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.